Introduction

In 2007, BGI came to Shenzhen and established BGI Research. BGI Research follows the academic tradition and innovative spirit of BGI, with a focus on novel scientific research with a good application value. The Institute is dedicated to the research of genomes, tumors, brain science, reproductive health and animal and plant molecular breeding. Based on major scientific projects on human health, animals, plants and microorganisms, the Institute conducts in-depth scientific research and core technology development at DNA level, RNA level, DNA and histone modification level, protein level, network/system biology level, tuple level, population and evolutionary omics levels, metabolomics levels, synthetic biology levels and the single cell level.

        In January 2011, the National Development and Reform Commission approved Shenzhen to establish the China National Genebank, relying on the support of BGI Research. In October of the same year, China National Genebank Construction Program won approval of National Development and Reform Commission, the Ministry of Finance, the Ministry of Industry and Information Technology, and the former Ministry of Health of the four ministries and commissions. On September 22, 2016, the China National Genebank was officially put into operation. The China National Genebank aims to “maintain the international competitiveness and influence in genetic field” and it's mission is “leading the exploration and experimental park of China's innovative science and technology to support the resources and basic capabilities platform of China's life sciences and life economic development”. The China National Genebank is building a public welfare, open, supportive, and leading service platform for genetic resources mining based on it's ability of storing, reading, and writing massive biological resources. The China National Genebank consists of 6 parts: bio-repository, bioinformatics data center, living biobank, digitalization platform and synthetic and editing platform.

Established in 2011, BGI College's mission is to “improve disciplines, industry and talents via real world projects. BGI College relies on BGI's powerful research platforms, major scientific research projects and industrial development chain to carry out an innovative genomics curriculum . BGI college is dedicated to international open education and training innovative talents that are needed for scientific research and industrial development in the life sciences.

        GigaScience aims to revolutionize publishing by promoting reproducibility of analyses and data dissemination, organization, understanding, and use. As an open access and open-data journal, GigaScience publishes ALL research objects (data, software tools and workflows) from 'big data' studies across the entire spectrum of life and biomedical sciences. These resources are managed using the FAIR Principles for scientific data management and stewardship that state that research data should be Findable, Accessible, Interoperable and Reusable.To achieve its goals, the journal has a novel publication format: one that links standard manuscript publication with an extensive database that hosts all associated data and provides data analysis tools and cloud-computing resources. GigaDB provides a direct link between the published manuscript and the relevant supporting data. GigaScience have also built GigaGalaxy, a Galaxy-based data analysis platform to host computational methods and workflows, maximizing use of the data, tools and workflows in our papers in a more accessible and reproducible environment.

    On July 14, 2017, BGI Genomics was officially listed and became the 2001st listed company of the Shenzhen Stock Exchange. BGI Genomics is one of the world's leading genomics test and research service providers, providing genomics test and research services for medical institutions, research institutions, enterprises and institutions through genetic testing and other means. BGI Genomics is committed to helping and accelerating scientific innovation, strengthening the prevention and control of cancer and other genetic diseases, improving diagnostic tools for the rapid diagnosis of infectious disease and helping the development of precision medicine. Relying on cutting edge bioinformatics pipelines, advanced R&D, high-performance proprietary NGS sequencing technology, mass spectrometers,and underpinned by a decade of commercial experience, BGI Genomics provides its customers with expert and affordable clinical molecular diagnostic solutions and NGS services for research.

MGI Tech Co., Ltd. (MGI), a subsidiary of BGI Group, is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary DNBseq™ Nanoball Technology, MGI produces sequencing devices, equipment, consumables and reagents to support life science research, medicine and healthcare.

MGI's multi-omics platforms include genetic sequencing, mass spectrometry and medical imaging. Providing real-time, comprehensive, life-long solutions, its mission is to develop and promote advanced life science tools for future healthcare.MGI's mission is to enable effective and affordable healthcare solutions for all, with a vision to develop and promote advanced life science tools for future healthcare

BGI Forensic Science and Technology Co., Ltd. (hereinafter referred to as “FGI”) is committed to developing scientific technology in order to enable accurate judicial appraisal. FGI is the first third-party accredited institute approved by the Ministry of Justice and is acknowledged by well-known genomics experts and forensic material identification experts both domestically and abroad. FGI offers a new generation of DNA technology testing platforms and ISO17025 national laboratories, which have won recognition by the CNAS forensic appraisal/forensic science institution. FGI seeks to be a judicial science and technology innovation institution, integrating production, learning, research and application.